Crushed recycled glass as a substrate for constructed wetland wastewater treatment: a case study of its potential to facilitate pharmaceutical removal.

The use of recycled glass as a substrate for constructed wetlands was assessed through two studies. The first study examined the dissipation of atenolol, carbamazepine, and sulfamethoxazole in mesocosm-modeled wetlands using glass or limestone gravel as substrates, with or without cattails (Typha spp.). Following pseudo-first-order kinetics, atenolol dissipated the fastest from the water surface of the mesocosms (t1/2~1 day), followed by sulfamethoxazole (t1/2~14 days), and carbamazepine (t1/2~48 days), with no significant differences across treatments. Increased half-lives were observed at greater depth, likely due to light screening. A Monte Carlo sensitivity analysis diagnosed sunlight absorption rates and second-order hydroxyl-mediated indirect photolysis rates to be the main sources of uncertainty in our dissipation rate estimates, compared to our observed rates. The second study examined in situ pharmaceutical removal in tertiary pilot-scale subsurface filters made of crushed recycled glass or sand in a wastewater treatment facility in Manitoba, Canada. Glass and sand showed no significant differences for pharmaceutical removals; atenolol and metoprolol were removed below limits of detection, while carbamazepine and sulfamethoxazole persisted over a retention time of 24 h. Overall, recycled glass performed similarly to traditional substrates for wetland-based wastewater treatment.

Wastewater sources of per- and polyfluorinated alkyl substances (PFAS) and pharmaceuticals in four Canadian Arctic communities.

Effective removal of organic contaminants in wastewater effluent poses a challenge to small communities worldwide, particularly in the Arctic due to infrastructure challenges and harsh climates. To understand better the efficacy of current treatment options and risks posed by pharmaceuticals and pesticides on receiving waters in the Arctic, four representative human communities in Nunavut, Canada were evaluated. Per- and polyfluorinated alkyl substances (PFASs) were also investigated in one community. These communities have treatment ranging from primary lagoons, engineered wetlands, and natural lakes. Pharmaceuticals and pesticides were measured using the organic diffusive gradients in thin film (o-DGT) passive sampler in summer 2018. Of the 34 compounds studied, seven pharmaceuticals were found at least once: atenolol, carbamazepine, metoprolol, naproxen, sulfapyridine, sulfamethoxazole, and trimethoprim. With the exception of 5210 ng naproxen/L in Iqaluit, most receiving waters showed negligible amounts of contamination. Iqaluit had the poorest overall system performance while Baker Lake had the best. Measured pharmaceutical concentrations do not appear to pose a significant acute hazard to receiving waters at this time, based on known toxicological endpoints. PFAS concentrations were found to be over 100-fold greater in Cambridge Bay wastewater than previously reported Arctic seawater. Results suggest that wastewater may be an important point source of PFASs in Arctic communities. The o-DGT passive samplers performed well in marine Arctic settings. We recommend further testing of wastewater efficiencies in Arctic communities along with evaluations of seasonal variations.

Attenuation of pharmaceuticals, nutrients and toxicity in a rural sewage lagoon system integrated with a subsurface filtration technology.

Although many studies have addressed the ability of subsurface filtration systems to remove emerging contaminants from wastewater at micro- and mesocosm-scale, little is known about their performance on full-scale wastewater treatment facilities. To understand better how effective these systems can be for municipal wastewater polishing, we assessed the ability of a full-scale lagoon-subsurface filter system located in Dunnottar, Manitoba, Canada, to attenuate regulatory wastewater parameters, nutrients, pharmaceuticals, and toxicity over the course of the discharge periods in 2015 and 2016 (June-October). Pharmaceuticals included ß-blockers, anticonvulsant drugs, and macrolide and sulfonamide antibiotics. Out of six consistently detected pharmaceuticals, four were efficiently removed through lagoon treatment (e.g. clarithromycin, metoprolol, propranolol), while two persisted to a certain extent (e.g. carbamazepine, sulfamethoxazole), even after subsurface filtration. Attenuation was observed for nutrients with averages of 40% and 60% for ammonia and total phosphorus respectively within the filter, consistent with previous pilot-scale studies at this facility. Compliance with regulations for conventional wastewater parameters at the effluent was observed, as well as reduced acute toxicity (as determined by Microtox®) from the primary lagoon to the effluent, and little likelihood of acute toxicity in receiving waters. Our results suggest that first, the full-scale system has an overall similar performance when compared to the previously studied pilot-scale system; second, there was no apparent effect of acclimation on the attenuation of studied contaminants or toxicity; and finally, the concentrations of contaminants do not appear to pose an acute risk for aquatic species in the receiving environment.

The release of wastewater contaminants in the Arctic: A case study from Cambridge Bay, Nunavut, Canada.

The treatment of municipal wastewater in the Arctic is challenging due to a variety of financial, operational, climatic and technical issues. To better understand the efficacy of current wastewater treatment in this region and the hazard posed to receiving waters, we assessed the occurrence of nutrients and contaminants (i.e., pharmaceuticals, antibiotic resistance genes) as they moved through a lagoon-based treatment system in Cambridge Bay, Nunavut, Canada. Wastewater treatment in this community is performed by the use of a lagoon-tundra wetland system that is discharged into the marine environment and is representative of current common practices throughout the region. In 2014, samples were collected before and during lagoon discharge from two locations in the main lagoon, one location downstream from the lagoon effluent and three locations offshore. Grab samples were collected to measure nutrients (e.g., total nitrogen and phosphorus) and the presence of antibiotic resistance gene-bearing microbes, and Polar Organic Chemical Integrative Samplers (POCIS) were deployed to collect passively organic contaminants in all locations. A total of six pharmaceuticals were detected from a screen of twenty-eight analytes during the study: atenolol, carbamazepine, clarithromycin, metoprolol, sulfamethoxazole and trimethoprim. The greatest concentrations of nutrients, antibiotic resistance genes (ARGs), and pharmaceuticals were found in sampling locations within the treatment lagoon. Offshore of the release point, we observed limited to no detection of pharmaceuticals and ARGs, but no change in total nitrogen and phosphorus from pre-release. We conclude that the current concentrations of monitored pharmaceuticals do not pose a significant hazard at this time to aquatic organisms in Cambridge Bay.